Drug Information Update- FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies

Drug Information Update- FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies

The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The U.S. Food and Drug Administration today announced the availability of the first draft guidance for industry on Risk Evaluation and Mitigation Strategies or REMS, which are required for certain drugs or biologics.
The Food and Drug Administration Amendments Act of 2007 (FDAAA) granted the FDA the authority to require the submission and implementation of a REMS if the FDA determines a REMS is necessary to ensure that a drug’s benefits outweigh its risks.
REMS components include medication guides; patient package inserts; a communication plan for health care providers; elements to ensure safe use including requirements for those who prescribe, dispense, or use the drug; and a timetable for REMS submission.
The draft guidance for industry titled “Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications”:
provides FDA’s current thinking on the format and content that industry should use for submissions of proposed REMS
describes each potential element
includes preliminary information on the content of assessments and proposed modifications of approved REMS
describes REMS policies for certain regulatory situations
informs industry about who to contact within FDA about a REMS
indicates FDA Web sites where documents about approved REMS will be posted
provides an example of what an approved REMS might look like for a fictitious product.
“With this new guidance, manufacturers will have a useful blueprint for how to develop these important safety strategies,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research.
The draft guidance is available at: REMS Guidance

abrir aquí para acceder al documento FDA en PDF (39 páginas):
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf